Skip to main
BNTC
BNTC logo

BNTC Stock Forecast & Price Target

BNTC Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Benitec Biopharma Inc is demonstrating strong potential for positive advancements in its therapeutic development for Oculopharyngeal Muscular Dystrophy (OPMD), evidenced by consistent improvements observed in three patients during follow-ups, indicating the efficacy of its treatment approach. The company is on track to double its patient cohort from three to six in the fourth quarter, which could serve as a critical catalyst for further enhancing its clinical outcomes and data robustness. Additionally, with plans to escalate to a higher dose in the fourth quarter of 2025, Benitec Biopharma is positioning itself strategically to advance its innovative genetic medicines, reflecting a favorable outlook for sustained development and potential market impact.

Bears say

Benitec Biopharma Inc is facing significant challenges that contribute to a negative outlook on its stock. The company is at risk of delays or failures in obtaining regulatory approval for its therapies, particularly BB-301, which could adversely affect its share price and investor confidence. Furthermore, the anticipated need for additional equity financing raises concerns about dilution for existing shareholders, compounding the financial risks associated with the inherent uncertainties of clinical trials and competitive pressures in the biotechnology sector.

BNTC has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Benitec Biopharma Limited Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Benitec Biopharma Limited Sponsored ADR (BNTC) Forecast

Analysts have given BNTC a Buy based on their latest research and market trends.

According to 6 analysts, BNTC has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Benitec Biopharma Limited Sponsored ADR (BNTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.